MC
TGTX icon

Maverick Capital’s TG Therapeutics TGTX Stock Holding History

Maverick Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,318,700
Closed -$51.1M – 542
2022
Q4 		$51.1M Sell
4,318,700
-3,383,170
-44% -$24.6M 1.21% 24
2022
Q3 		$45.6M Buy
7,701,870
+954,321
+14% +$6.26M 1.03% 20
2022
Q2 		$28.7M Buy
6,747,549
+69,823
+1% +$436K 0.71% 32
2022
Q1 		$63.5M Buy
6,677,726
+642,851
+11% +$7.44M 1.12% 23
2021
Q4 		$115M Buy
6,034,875
+2,738,424
+83% +$71.1M 1.3% 19
2021
Q3 		$110M Buy
3,296,451
+475,372
+17% +$14.7M 1.11% 20
2021
Q2 		$109M Sell
2,821,079
-150,057
-5% -$5.89M 1.03% 19
2021
Q1 		$143M Sell
2,971,136
-230,925
-7% -$11.1M 1.32% 13
2020
Q4 		$167M Sell
3,202,061
-1,190,135
-27% -$40.2M 2.67% 11
2020
Q3 		$118M Buy
4,392,196
+4,262,157
+3,278% +$98.1M 2.18% 15
2020
Q2 		$2.53M Buy
+130,039
New +$2.09M 0.05% 137

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Maverick Capital's TGTX Position: Q1 2023 in Review

Maverick Capital sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 4,318,700 shares — an estimated $51.1M sold.

Maverick Capital first reported a position in TGTX in Q2 2020 and held it in 11 quarters. The position peaked at $167M in Q4 2020. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Maverick Capital reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Maverick Capital sold 4,318,700 TG Therapeutics shares in Q1 2023, an estimated $51.1M.
  • Maverick Capital first reported a position in TG Therapeutics in Q2 2020 and held it in 11 quarters.
  • Maverick Capital's TG Therapeutics position peaked at $167M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Maverick Capital's 13F filing for Q1 2023, filed 15 May 2023.